semaglutide deaths Recent reports link around 10 and 100 hospitalizations in the U.S. to compounded versions of semaglutide, sold under the brand name Ozempic by Novo Nordisk. The company has raised concerns with Novo kidney trial finds Ozempic
Description
No, GLP-1 receptor agonists are not licensed or recommended for treating IBS

Reports like the one from UAB may support claims that labeling and usage guidance do not provide sufficient safeguards for real-world use

Tushuizen, Adriaan G

When will Retatrutide be available by prescription
